Reuters logo
BRIEF-Blueprint Medicines announces proof-of-concept data from Phase 1 clinical trial of BLU-285
November 30, 2016 / 11:10 PM / a year ago

BRIEF-Blueprint Medicines announces proof-of-concept data from Phase 1 clinical trial of BLU-285

Nov 30 (Reuters) - Blueprint Medicines Corp

* Blueprint Medicines announces proof-of-concept data from Phase 1 clinical trial of BLU-285 in patients with advanced gastrointestinal stromal tumors

* As of data cutoff date of November 1, 2016, BLU-285 was observed to be well-tolerated at all doses Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below